BioRestorative Therapies Inc (BRTX) - Total Liabilities
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has total liabilities worth $1.61 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BRTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
BioRestorative Therapies Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how BioRestorative Therapies Inc's total liabilities have evolved over time, based on quarterly financial data.
BioRestorative Therapies Inc Competitors by Total Liabilities
The table below lists competitors of BioRestorative Therapies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tatton Asset Management plc
LSE:TAM
|
UK | GBX13.18 Million |
|
Signature Resources Ltd
V:SGU
|
Canada | CA$2.45 Million |
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
Romania | RON121.74K |
|
Sonoro Energy Ltd
V:SNV
|
Canada | CA$1.04 Million |
|
JPMorgan UK Small Cap Growth & Income Plc
LSE:JUGI
|
UK | GBX63.64 Million |
|
Organoclick AB
ST:ORGC
|
Sweden | Skr128.92 Million |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
USA | $51.14 Million |
|
Inca Minerals Ltd
AU:ICG
|
Australia | AU$283.19K |
Liability Composition Analysis (2009–2025)
This chart breaks down BioRestorative Therapies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BRTX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioRestorative Therapies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioRestorative Therapies Inc (2009–2025)
The table below shows the annual total liabilities of BioRestorative Therapies Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.72 Million | -0.68% |
| 2024-12-31 | $3.75 Million | +43.76% |
| 2023-12-31 | $2.61 Million | -57.57% |
| 2022-12-31 | $6.14 Million | +617.38% |
| 2021-12-31 | $856.50K | -84.92% |
| 2020-12-31 | $5.68 Million | -60.13% |
| 2019-12-31 | $14.24 Million | +44.84% |
| 2018-12-31 | $9.83 Million | +14.41% |
| 2017-12-31 | $8.60 Million | +30.62% |
| 2016-12-31 | $6.58 Million | +11.05% |
| 2015-12-31 | $5.93 Million | -30.94% |
| 2014-12-31 | $8.58 Million | +6.35% |
| 2013-12-31 | $8.07 Million | +25.87% |
| 2012-12-31 | $6.41 Million | +64.04% |
| 2011-12-31 | $3.91 Million | +222.20% |
| 2010-12-31 | $1.21 Million | +297.62% |
| 2009-12-31 | $305.00K | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more